Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Retinal Vasculature Pathology Linked With MS Disease Burden
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
Keratinocyte Cancers Most Commonly Located on the Head and Neck, US Study Finds
Frameworks for Advancing Health Equity: Urban Health Outreach
What We’re Reading: Long COVID Initiative Failure; Third Human Bird Flu Case; Weight-Loss Drug Coverage Issues
BET Inhibition Reduces CLL Burden, Boosts Immune Function